The Efficacy and Safety of Medicurtain® in Patients With Hysteroscopy (Pivotal Study)

Not Applicable

Completed

• Conditions: Intrauterine Synechiae; Tissue Adhesion, Surgery-Induced
• Interventions: Device: Placebo; Device: Medicurtain®

• Registration Number: NCT04638855
• Lead Sponsor: Shin Poong Pharmaceutical Co. Ltd.

Brief Summary

This study was designed to assess the safety and efficacy of MEDICURTAIN, an adhesion barrier in patients who underwent hysteroscopy with uterine polyp or endometrial myoma or missed abortion (uterine lesion suspected to be associated with pregnancy) or intrauterine adhesion. Adhesion formation in both groups was evaluated by the grading scale and photographs taken during the follow up to evaluate the safety and efficacy of the product.

Detailed Description

This study was designed as a multi-center, randomized, evaluator-blinded and placebo-comparative study. A woman aged 20-80 years scheduled for the hysteroscopy was eligible to participate in the study. Subject screening was conducted for the subject who signed an informed consent form. Subjects who met the inclusion/exclusion criteria were randomly assigned into either treatment or no-treatment control group. Follow-up visits were performed at 1 week (Visit 2) and 4 weeks (Visit 3) after the index surgery. Telephone call is made between 1 to 2 weeks prior to the Visit 3 for the information for the follow-up visit and check-up.

At Visit 2 (at Week 1 after the index surgery, a window of ± 2 days was allowed), assessments to identify adverse events and general health conditions, and surgery satisfaction survey were performed. At Visit 3 (at Week 4 ± 4 days), adverse event assessments and general satisfaction survey were performed, and adhesion formations and grades were evaluated. The presence or absence of adhesions, and their grades at Visit 3 (at Week 4 ± 4 days) were assessed in an evaluator-independent manner.

Adhesion formations rate (Primary endpoint) and adhesion grade(secondary endpoint) were assessed at Week 4 after the index surgery (Visit 3), based on the video clips and still images captured via a video monitor during a second-look hysteroscopy, by inserting the hysteroscope (5 -10 mm diameter) into the uterine through the vagina; and graded in an evaluator-blinded manner by an independent evaluator, who did not take part in the index surgery or application of Medicurtain®. Intrauterine adhesion grades were assessed by using the American Fertility Society (AFS) adhesion score established in 1988. It was classified as 4 grading scales (0, 1, 2 and 3 grade). Grade 0 (none) means no adhesion, while Grade 1 to Grade 3 means there are adhesions and severity increased with the grade. Adhesion formation rate and grade in the treated or in the non-treated control groups were compared and evaluated using the Grade 0 to 3 adhesion scoring system.

Study Timeline

• Study Start: 2010-09-08
• Primary Completion: 2011-12-03
• Study Completion: 2011-12-03
• Study First Submitted: 2020-11-16
• Study First Submitted QC: 2020-11-16
• Study First Posted: 2020-11-20
• Status Verified: 2021-09
• Last Update Submitted: 2021-09-28
• Last Update Posted: 2021-09-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 223

Inclusion Criteria

1. Woman who is between 20~80 years of age.

2. Woman who is reserved elective hysteroscopy for

   • Uterine polyp
   • Uterine (endometrium) myoma
   • Missed miscarriage (uterine lesion suspected to be associated with pregnancy)
   • Adhesion in uterine

3. Woman who signed an informed consent form prior to the investigation.

Exclusion Criteria

1. Presence of tumor or inflammatory disease in other organs.
2. Subject who is not eligible for anesthesia or re-operation due to other disease confirmed by investigator.
3. Subject who is not eligible for re-operation or hysteroscopy
4. Any condition which made a subject unsuitable for inclusion in the discretion of the Investigator will be excluded.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	No device after hysteroscopy surgery
Medicurtain®	Medicurtain®	Treat Medicurtain 5ml prefilled syringe after hysteroscopy surgery

Primary Outcome Measures

Name	Time	Method
Outcome Measure: comparison between treated group and untreated control group for the adhesion rate	4 weeks	Adhesion rate: {(number of subjects occurred adhesion formation for each group)/ (number of subjects for each group)} \* 100

Secondary Outcome Measures

Name	Time	Method
The incidence rate of serious adverse events	follow up to 4 weeks	Safety and tolerability by collecting serious adverse events (SAEs)
The incidence rate of adverse events	follow up to 4 weeks	Safety and tolerability by collecting adverse events (AEs)
The incidence rate of adverse drug reaction	follow up to 4 weeks	Safety and tolerability by collecting adverse drug reaction (ADRs)
Comparison of Adhesion Grade between treated group and untreated control group	4 weeks	Adhesive grade evaluation standards are classified into Grade 0(Non), Grade 1(Mild), Grade 2(Moderate), Grade 3(Severe).

Trial Locations

Locations (1)

Gangnam Severance Hospital; 🇰🇷 Seoul, Korea, Republic of